<DOC>
	<DOCNO>NCT02633826</DOCNO>
	<brief_summary>This investigator-initiated study analyse role pre-formed alloreactive T cell acute rejection episode graft outcome kidney transplant recipient live donation .</brief_summary>
	<brief_title>Pre-formed Alloreactivity Renal Transplant Recipients</brief_title>
	<detailed_description>In recipient solid organ transplant , preform alloreactive T cell may mediate acute rejection compromise long-term graft survival . Previous study role alloreactive T cell transplantation hamper fact experimental assay quantify alloreactivity technically demand suitable use clinical setting . Based recent development whole-blood assay , alloreactive T cell may quantify characterise within one day . This assay therefore provide experimental basis study development role alloreactive T cell clinical set patient renal transplantation . This perform multicenter study live donor renal transplant recipient preform alloreactivity recipient towards live donor determine associated standard clinical parameter graft function long-term graft outcome follow-up . In addition , development donor-specific antibody analyse transplantation . If project able provide evidence role alloreactive T cell acute rejection episodes long-term graft function , assay may future use guide individualized immunosuppressive drug treatment early transplantation . It thereby aid distinguish patient standard immunosuppressive drug regimen sufficient minor population patient high risk rejection benefit intensified drug regimen .</detailed_description>
	<criteria>Written inform consent First second renal transplantation Living donor renal transplantation Recipient old 18 year Negative cross match Planed quadruple , Tacrolimusbased ( lowdose ) immunosuppressive drug regimen ( Tacrolimus , 2g MMF start dose , ( methyl ) prednisolone accord center practice , basiliximab day 0 day 4 ) Planned start Tacrolimus ( Advagraf® ) 3 10 day prior transplantation ( trough level 510 ng/ml first 3 month , 57 ng/ml thereafter ) Planed Tcell deplete induction therapy Pregnancy Preexisting , moderate high dose immunosuppressive medication Preexisting , severe lymphopenia ( &lt; 400/µl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>alloreactive T cell</keyword>
	<keyword>donor-specific antibody</keyword>
</DOC>